mom2lillian
New member
Just FYI I got this in email this morning
<a target=_blank class=ftalternatingbarlinklarge href="http://www.boston.com/business/globe/articles/2007/08/13/22m_to_help_develop_drug_for_cystic_fibrosis/
">http://www.boston.com/business..._for_cystic_fibrosis/
</a>
We have negotiated one of our largest biotechnology collaborations to date, with a Boston-area firm called FoldRx. We will pay FoldRx $22 million over five years to discover and develop new compounds to treat the core defect in cystic fibrosis.
We're particularly excited about this alliance because FoldRx will apply novel, proprietary technology that could improve the function of a misfolded protein associated with CF.
This collaboration - along with many others, including Vertex, CombinatorRx, and Epix - is exciting because it's identifying new ways to treat the basic CF defect.
We can all feel proud that CFF is a pioneer in the area now known as "venture philanthropy." In fact, since 1999, when we launched the Therapeutics Development Program, we have committed over $250 million for CF research by biotechnology companies. Recently, an industry publication called CenterWatch noted that CFFT will spend $48 million with biotechs this year alone--representing the bulk of the $75 million that voluntary health organizations will spend this year on drug research.
It is also gratifying that we are seeing improvement in the length and quality of life for all patients, as we await new therapies that could cure CF.
BOB
Robert J. Beall, Ph.D.
President and CEO
Cystic Fibrosis Foundation
6931 Arlington Road
Bethesda, MD 20814
301-907-2541 Phone
301-907-2699 Fax
mailto:rjb@cff.org
<a target=_blank class=ftalternatingbarlinklarge href="http://www.boston.com/business/globe/articles/2007/08/13/22m_to_help_develop_drug_for_cystic_fibrosis/
">http://www.boston.com/business..._for_cystic_fibrosis/
</a>
We have negotiated one of our largest biotechnology collaborations to date, with a Boston-area firm called FoldRx. We will pay FoldRx $22 million over five years to discover and develop new compounds to treat the core defect in cystic fibrosis.
We're particularly excited about this alliance because FoldRx will apply novel, proprietary technology that could improve the function of a misfolded protein associated with CF.
This collaboration - along with many others, including Vertex, CombinatorRx, and Epix - is exciting because it's identifying new ways to treat the basic CF defect.
We can all feel proud that CFF is a pioneer in the area now known as "venture philanthropy." In fact, since 1999, when we launched the Therapeutics Development Program, we have committed over $250 million for CF research by biotechnology companies. Recently, an industry publication called CenterWatch noted that CFFT will spend $48 million with biotechs this year alone--representing the bulk of the $75 million that voluntary health organizations will spend this year on drug research.
It is also gratifying that we are seeing improvement in the length and quality of life for all patients, as we await new therapies that could cure CF.
BOB
Robert J. Beall, Ph.D.
President and CEO
Cystic Fibrosis Foundation
6931 Arlington Road
Bethesda, MD 20814
301-907-2541 Phone
301-907-2699 Fax
mailto:rjb@cff.org